Efficacy and safety of octreotide treatment for diazoxide‐unresponsive congenital hyperinsulinism in China
ABSTRACT Importance Octreotide is an off‐label medicine for congenital hyperinsulinism (CHI), but is currently widely used for treatment of patients with CHI. Thus far, variable efficacy and adverse effects have been reported for octreotide. Objective The present study evaluated the efficacy and saf...
Saved in:
Main Authors: | Bingyan Cao (Author), Wu Di (Author), Chang Su (Author), Jiajia Chen (Author), Xuejun Liang (Author), Min Liu (Author), Wenjing Li (Author), Xiaoqiao Li (Author), Chunxiu Gong (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A novel mutation of gene in a patient with diazoxide-unresponsive congenital hyperinsulinism
by: Ji Sook Park, et al.
Published: (2016) -
Using low-dose octreotide with diazoxide-resistant congenital hyperinsulinism resulting from compound heterozygous mutations in the gene
by: Kyujung Park, et al.
Published: (2022) -
Novel Compound Heterozygous Variants of the <i>ABCC8</i> Gene Warrant Identification of Pancreatic Histology in Infant with Diazoxide-unresponsive Congenital Hyperinsulinism
by: Rana Al Balwi, et al.
Published: (2021) -
Clinical features and predictors of remission in children under the age of 7 years with Graves' disease
by: Yi Gu, et al.
Published: (2020) -
Octreotide Infusion for the Treatment of Congenital Chylothorax
by: Sumayyah Ahmed Nezar Kobeisy, et al.
Published: (2020)